Source and scope
This summary is bounded to the recommendations, population and decisions covered by Canadian guidelines for the management of plaque psoriasis. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:Canadian psoriasis guideline
Source-attributed clinical priorities
- Assess body and high-impact sites, symptoms, quality of life, joint disease and cardiometabolic comorbidity.
- Use topical therapy for limited disease and phototherapy or systemic options for more extensive or high-impact disease.
- Refer suspected psoriatic arthritis, erythroderma, pustular disease or treatment-refractory psoriasis promptly.
- Ask about joint pain, morning stiffness, dactylitis and enthesitis at every severity level.
sources for this section:Canadian psoriasis guideline
Practical assessment and management workflow
1
Assess body surface and high-impact sites, itch, pain, nails, quality of life and prior treatment.
2
Screen cardiometabolic risk, mood, inflammatory bowel disease and medication triggers.
3
Use topical treatment matched to site and arrange phototherapy or systemic care for extensive or high-impact disease.
4
Monitor response and treatment-specific laboratory, infection and reproductive safety.
sources for this section:Canadian psoriasis guideline
Safety, red flags and urgent escalation
- Erythroderma, generalized pustular disease or systemic illness needs urgent specialist assessment.
- A hot swollen joint or rapidly progressive inflammatory arthritis warrants expedited evaluation.
- Avoid abrupt withdrawal of systemic corticosteroids used for another reason without a coordinated plan.
sources for this section:Canadian psoriasis guideline
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:Canadian psoriasis guideline
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Canadian psoriasis guideline
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Canadian Psoriasis Guidelines CommitteeCanadian guidelines for the management of plaque psoriasisaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.